27 Drydock Avenue
8th Floor
Boston, MA 02210
United States
877 422 5362
https://www.ginkgobioworks.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 641
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Jason Kelly | Founder, CEO & Director | 262.5k | N/D | 1981 |
Dr. Reshma P. Shetty | Founder, Pres, COO & Director | 262.5k | N/D | 1981 |
Mr. Mark E. Dmytruk | Chief Financial Officer | 439.5k | N/D | 1971 |
Mr. Thomas Knight Jr. | Founder | N/D | N/D | N/D |
Mr. Austin Che | Founder, Head of Strategy & Treasurer | N/D | N/D | N/D |
Mr. Bartholomew Canton | Founder, CTO & Sec. | N/D | N/D | N/D |
Marie E Fallon | Chief Accounting Officer | N/D | N/D | N/D |
Karen Tepichin | Gen. Counsel & Sec. | N/D | N/D | N/D |
Ms. Anna Marie Wagner | Sr. VP of Corp. Devel. | N/D | N/D | N/D |
Ms. Samantha Sutton | Head of People | N/D | N/D | N/D |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
La calificación ISS Governance QuickScore de Ginkgo Bioworks Holdings, Inc. a partir del 1 de febrero de 2023 es 9. Las puntuaciones principales son Auditoría: 5; Junta: 8; Derechos del accionista: 10; Compensación: 7.